MTOR and idiopathic pulmonary fibrosis: Recent clinical trials demonstrated that short-term treatment with sirolimus, an mTOR inhibitor, led to a decrease in the levels of circulating fibrocytes in individuals with IPF, accompanied by an acceptable safety profile36.